Aptevo Therapeutics Inc (APVO)
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for cancer treatment in the United States. The company uses its ADAPTIR and ADAPTIR-FLEX platform technologies to design mono-, bi-, and multi-specific antibody candidates intended to support the immune system in targeting cancer cells. Its most advanced program is mipletamig, a lead blood cancer candidate in a Phase 1b/2 study for acute myelogenous leukemia. Other programs include ALG.APV-527, a Phase 1 investigational bispecific candidate being studied across several solid tumors; APVO603, a preclinical dual agonist bispecific candidate; APVO442, a preclinical bispecific program based on ADAPTIR-FLEX; and APVO711, a preclinical dual mechanism candidate for prostate cancer. Aptevo was incorporated in 2016 and is headquartered in Seattle, Washington.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APVO
|
$7.13
|
58.5% Upside
|
Bargain
|
$25.50
|
466.7% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.2x
|
0.5x
|
—
|
5.925 M
|
-4.496 M
|
42.7%
|
87.8%
|
-46.8
|
—
|
102.4%
|
